リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「An analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

An analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging

Hatoko, Tomonobu 京都大学 DOI:10.14989/doctor.k24517

2023.03.23

概要

www.nature.com/scientificreports

OPEN

An analysis of intestinal
morphology and incretin‑producing
cells using tissue optical clearing
and 3‑D imaging
Tomonobu Hatoko1, Norio Harada1*, Shinsuke Tokumoto1, Shunsuke Yamane1,
Eri Ikeguchi‑Ogura1, Tomoko Kato1, Takuma Yasuda1, Hisato Tatsuoka1,
Satoko Shimazu‑Kuwahara1,2, Daisuke Yabe3, Yoshitaka Hayashi4 & Nobuya Inagaki1*
Tissue optical clearing permits detailed evaluation of organ three-dimensional (3-D) structure as well
as that of individual cells by tissue staining and autofluorescence. In this study, we evaluated intestinal
morphology, intestinal epithelial cells (IECs), and enteroendocrine cells, such as incretin-producing
cells, in reporter mice by intestinal 3-D imaging. 3-D intestinal imaging of reporter mice using optical
tissue clearing enabled us to evaluate both detailed intestinal morphologies and cell numbers, villus
length and crypt depth in the same samples. In disease mouse model of lipopolysaccharide (LPS)injected mice, the results of 3-D imaging using tissue optical clearing in this study was consistent with
those of 2-D imaging in previous reports and could added the new data of intestinal morphology. In
analysis of incretin-producing cells of reporter mice, we could elucidate the number, the percentage,
and the localization of incretin-producing cells in intestine and the difference of those between L cells
and K cells. Thus, we established a novel method of intestinal analysis using tissue optical clearing and
3-D imaging. 3-D evaluation of intestine enabled us to clarify not only detailed intestinal morphology
but also the precise number and localization of IECs and incretin-producing cells in the same samples.
Abbreviations
IEC Intestinal epithelial cell
EC Enteroendocrine cell
GLP-1 Glucagon-like peptide-1
GIP Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
CUBIC Clear, unobstructed brain/body imaging cocktails and computational analysis
3-D Three-dimensional
GFP Green fluorescent protein
LPS Lipopolysaccharide
The intestine is an important organ involved in digestion, absorption, and energy metabolic regulation such as
appetite regulation and nutrient accumulation through various intestinal ­hormones1. Intestinal epithelial cells
(IECs) are located at the boundary between the intestine and intestinal lumen and are composed of several
types of cells such as absorptive cells, goblet cells, Paneth cells, and enteroendocrine cells (ECs)2. Two major
incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory
polypeptide (GIP), are secreted from enteroendocrine L cells and K cells, respectively, in response to nutrient
­ingestion3–5, and have various biological effects such as enhancing glucose-dependent insulin secretion from
pancreatic β-cells6–8 and regulating body w
­ eight9–13. Thus, GLP-1 and GIP play a crucial role in glucose and
body weight control.

1

Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54
Kawahara‑cho, Shogoin, Sakyo‑ku, Kyoto 606‑8507, Japan. 2Preemptive Medicine and Lifestyle Related Disease
Research Center, Kyoto University Hospital, Kyoto, Japan. 3Department of Diabetes and Endocrinology, Graduate
School of Medicine, Gifu University, Gifu, Japan. 4Division of Stress Adaptation and Protection, Department
of Endocrinology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan. *email:
nharada@kuhp.kyoto-u.ac.jp; inagaki@kuhp.kyoto-u.ac.jp
Scientific Reports |

(2022) 12:17530

| https://doi.org/10.1038/s41598-022-22511-7

1
Vol.:(0123456789)

www.nature.com/scientificreports/
Immunohistological analysis of intestinal tissue sections generally has been used for evaluating the number
and localization of target cells in i­ntestine14. However, it is difficult to envision the three-dimensional (3-D)
structure of villi and crypts and to evaluate the number and localization of IECs and ECs under two-dimensional
(2-D) intestinal tissues.
Tissue optical clearing is an observational method that has shown remarkable progress in recent years. Clear,
unobstructed brain/body imaging cocktails and computational analysis (CUBIC) protocol were established in
2014, making the whole body transparent in mice and enabling detailed evaluation of each organ’s 3-D structure
and its cells by tissue staining and ­autofluorescence15–17. Thus, CUBIC protocol may facilitate not only visualization of 3-D intestinal imaging but also 3-D intestinal structure e­ valuation18,19.
In the present study, we succeeded in obtaining detailed 3-D intestinal imaging of reporter mice using the
CUBIC protocol and analyzing intestinal morphology, IECs, and ECs such as incretin-producing cells.

Materials and methods

Animals.  Villin, encoded by Villin1, is an actin binding protein expressed throughout the crypt-villus axis in
small intestine and colon of ­mice20,21. Villin1-Cre transgenic mice and Ai14 mice were previously generated (JAX
stock #004586, #007908) (Jackson Laboratory, Bar Harbor, ME)21,22. Villin1-Cre and Ai14 heterozygous (Villin1Tomato) mice, which enable visualization of IECs by tdTomato fluorescence, were generated by crossbreeding
Villin1-Cre transgenic mice and Ai14 homozygous mice. Analysis of intestinal morphology and IECs was performed using 13-week-old male Villin1-Tomato mice.
Glucagon-green fluorescent protein (GFP) knock-in (Gcg-GFP) heterozygous mice and GIP-GFP knockin (GIP-GFP) heterozygous mice, which enabled visualization of L cells and K cells, respectively, were previously ­generated23,24. Villin1-Tomato and Gcg-GFP or GIP-GFP heterozygous (Villin1-Tomato+ Gcg-GFP or
Villin1-Tomato+ GIP-GFP) mice, which enabled visualization of both IECs by tdTomato fluorescence and L
cells and K cells by GFP fluorescence, were generated by crossbreeding Villin1-Tomato mice and Gcg-GFP or
GIP-GFP homozygous mice. Analysis of incretin-producing cells was performed using 13-week-old male Villin1Tomato+ Gcg-GFP or Villin1-Tomato+ GIP-GFP mice. All mice had free access to standard rodent chow and
were housed in a temperature-controlled room with a light–dark cycle of 14:10 h. All animal experiments were
performed in compliance with ethical regulations in Kyoto University. Animal care and procedures were approved
by the Animal Care and Use Committee of Kyoto University Graduate School of Medicine (Medkyo18245). All
animals were handled in accordance with the ARRIVE guidelines.
Collection of intestine samples and tissue clearing.  Mice were anesthetized with intraperitoneal
injection of pentobarbital sodium (10  ml/kg) and transcardially perfused with ice-cold phosphate-buffered
saline (PBS) followed by ice-cold 4% (w/v) paraformaldehyde (PFA) (Wako Pure Chemical Industries, Osaka,
Japan) after insertion of a 23-gauge needle into the left ventricle. The small intestine and the colon of all mice
were excised. A total of five samples of about 1 cm of small intestine were collected, one each from the oral side
(S1) and the anal side (S5), one from the intermediate area between S1 and S5 (S3) and one each from the intermediate areas between S1 and S3 (S2) and between S3 and S5 (S4) of the small intestine (Supplemental Fig. 1A).
S1, S2–S3, and S4–S5 corresponded to duodenum, jejunum and ileum, respectively. A total of three samples of
colon were collected, one from the oral side (C1), center (C2) and anal side (C3) of the colon. All samples were
immediately immersed in PFA at 4 °C with gentle shaking overnight and washed three times for more than 2 h
each in PBS at room temperature with gentle shaking. All samples were immersed in 50% (v/v) CUBIC-L (Tokyo
Chemical Industry Co., Ltd, Tokyo, Japan) reagent (1: 1 mixture of water: CUBIC-L) at 37 °C with gentle shaking for 24 h followed by CUBIC-L at 37 °C with gentle shaking for 24 h. After washing in PBS, the samples were
immersed in 5 ng/ml 4′,6-diamidino-2-phenylindole (DAPI) (Dojindo Laboratories, Kumamoto, Japan) in PBS
at room temperature with gentle shaking for 30 min followed by washing in PBS. The samples were immersed
in 50% (v/v) CUBIC-R+ (Dojindo Laboratories) reagent (1: 1 mixture of water: CUBIC-R+) for 24 h followed by
immersion in CUBIC-R+ at room temperature with gentle shaking for 24 h.
Lipopolysaccharide (LPS)‑induced intestinal injury and infection model mice.  13-week-old

male Villin1-Tomato mice were injected intraperitoneally with 10  mg/kg LPS from E. coli O111:B4 (SigmaAldrich, St. Louis, MO) in saline or an equivalent volume of saline ­alone25–27. After 24 h of injection, the mice
were anesthetized and transcardially perfused with the methods described above. Five samples of small intestine and three samples of colon in all mice were collected. In the 3-D imaging group, all samples in each five
LPS-injected mice and saline-injected mice (control mice) were cleared by CUBIC methods. In the 2-D imaging group, all samples in each three LPS-injected mice and control mice were fixed in 4% (w/v) PFA solution,
embedded in paraffin, and stained with hematoxylin and eosin (HE).

Image acquisition.  3-D fluorescence images were acquired by spinning disk confocal microscopy (Dragon-

fly, Andor Technology Ltd., Belfast, UK) on an IX83 (Olympus Corp. Tokyo, Japan) device through a UCPLFLN
20× objective lens (Olympus, numerical aperture [NA], 0.7) using a 405 nm laser for DAPI staining (blue), a
488 nm laser for GFP fluorescence imaging (green), and a 561 nm laser for tdTomato fluorescence imaging (red).
Data were collected in Spinning Disk 40 μm pinhole mode on a scientific complementary metal oxide semiconductor (sCMOS) camera (Zyla4.2Plus USB3) (Andor Technologies), which had a measured pixel size of 0.95 μm
× 0.95 μm. Using the Z scan mode, each sample was scanned every 2.5 μm in small intestine and colon. Acquired
microscopic images were further processed by the deconvolution algorithm for 3D volume reconstruction. ...

この論文で使われている画像

参考文献

1. Wang, Y. et al. Single-cell transcriptome analysis reveals differential nutrient absorption functions in human intestine. J. Exp. Med.

217, e20191130 (2020).

2. Kurashima, Y. & Kiyono, H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing.

Annu. Rev. Immunol. 35, 119–147 (2017).

3. Vollmer, K. et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes

57, 678–687 (2008).

4. Harada, N. et al. Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with

different factors in Japanese subjects. J. Diabetes Investig. 2, 193–199 (2011).

5. Joo, E. et al. Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice. Nutrition 63, 2332–2343 (2014).

6. Seino, Y., Fukushima, M. & Yabe, D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J. Diabetes Investig.

1, 8–23 (2010).

7. Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).

8. Kawasaki, Y. et al. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38

phosphorylation. Horm. Metab. Res. 42, 311–317 (2010).

9. Seino, Y. & Yabe, D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the

pancreas. J. Diabetes Investig. 4, 108–130 (2013).

10. Hayes, M. R., De Jonghe, B. C. & Kanoski, S. E. Role of the glucagon-like-peptide-1 receptor in the control of energy balance.

Physiol. Behav. 100, 503–510 (2010).

11. Kim, S. J. et al. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS ONE 7, e40156 (2012).

12. Nasteska, D. et al. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions.

Diabetes 63, 2332–2343 (2014).

13. Ogawa, E. et al. The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. Biochem.

Biophys. Res. Commun. 404, 115–120 (2011).

14. VanDussen, K. L. et al. Abnormal small intestinal epithelial microvilli in patients with Crohn’s disease. Gastroenterology 155,

815–828 (2018).

15. Susaki, E. A. et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell 157,

726–739 (2014).

16. Kubota, S. I. et al. Whole-body profiling of cancer metastasis with single-cell resolution. Cell Rep. 20, 236–250 (2017).

17. Tokumoto, S. et al. Generation and characterization of a novel mouse model that allows spatiotemporal quantification of pancreatic

β-cell proliferation. Diabetes 69, 2340–2351 (2020).

18. Xu, J., Ma, Y., Yu, T. & Zhu, D. Quantitative assessment of optical clearing methods in various intact mouse organs. J. Biophotonics

12, e201800134 (2018).

19. Bossolani, G. D. P. et al. Comparative analysis reveals Ce3D as optimal clearing method for in toto imaging of the mouse intestine.

Neurogastroenterology 31, e13560 (2019).

20. Rastlin, M. et al. The villin1 gene promotor drives cre recombinase expression in extraintestinal tissues. Cell Mol. Gastroenterol.

Hepatol. 10, 864–867 (2020).

21. El Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004).

22. Taniguchi, H. et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron 71,

995–1013 (2011).

23. Suzuki, K. et al. Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity. J. Biol. Chem. 288, 1929–1938 (2013).

24. Hayashi, Y. et al. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells

but not of intestinal L-cells. Mol. Endocrinol. 23, 1990–1999 (2009).

25. Perrone, E. E. et al. Dietary bile acid supplementation improves intestinal integrity and survival in a murine model. J. Pediatr. Surg.

45, 1256–1265 (2010).

26. Zhang, X. Y. et al. Propofol does not reduce pyroptosis of enterocytes and intestinal epithelial injury after lipopolysaccharide

challenge. Dig. Dis. Sci. 63, 81–91 (2018).

Scientific Reports |

Vol:.(1234567890)

(2022) 12:17530 |

https://doi.org/10.1038/s41598-022-22511-7

10

www.nature.com/scientificreports/

27. Wang, G. et al. Galactooligosaccharide pretreatment alleviates damage of the intestinal barrier and inflammatory responses in

LPS-challenged mice. Food Funct. 12, 1569–1579 (2021).

28. Stewart, J. S., Pollock, D. J., Hoffbrand, A. V., Mollin, D. L. & Booth, C. C. A study of proximal and distal intestinal structure and

absorptive function in idiopathic steatorrhoea. Q. J. Med. 36, 425–444 (1967).

29. Wang, T., Onouchi, T., Yamada, N. O., Matsuda, S. & Senda, T. A disturbance of intestinal epithelial cell population and kinetics

in APC1638T mice. Med. Mol. Morphol. 50, 94–102 (2017).

30. Lan, R., Li, Y., Chang, Q. & Zhao, Z. Dietary chitosan oligosaccharides alleviate heat stress-induced intestinal oxidative stress and

inflammatory response in yellow-feather broilers. Poult. Sci. 99, 6745–6752 (2020).

31. Tian, H. et al. Moringa oleifera polysaccharides regulates caecal microbiota and small intestinal metabolic profile in C57BL/6 mice.

Int. J. Biol. Macromol. 182, 595–611 (2021).

32. Li, C., Zhou, H. C., Nie, Y. L., Zhao, B. Y. & Wu, C. C. Effects of lipopolysaccharide on T lymphocyte cell subsets and cytokine

secretion in mesenteric lymph nodes of mice: Histological and molecular study. Environ. Toxicol. Pharmacol. 71, 103214 (2019).

33. Dong, N. et al. Astragalus polysaccharides alleviates LPS-induced inflammation via the NF-κB/MAPK signaling pathway. J. Cell

Physiol. 235, 5525–5540 (2020).

34. Iwasaki, K. et al. Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and

has a critical role in GIP secretion after fat ingestion. Endocrinology 156, 837–846 (2015).

35. Kogut, M. H., Lee, A. & Santin, E. Microbiome and pathogen interaction with immune system. Poult. Sci. 99, 1906–1913 (2020).

36. Darwich, A. S., Aslam, U., Ashcroft, D. M. & Rostami-Hodjegan, A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab. Dispos. 42, 2016–2222 (2014).

37. Leblond, C. P. & Stevens, C. E. The constant renewal of the intestinal epithelium in the albino rat. Anat. Rec. 100, 357–377 (1948).

38. Beumer, J., Gehart, H. & Clevers, H. Enteroendocrine dynamics—New tools reveal hormonal plasticity in the gut. Endocr. Rev.

41, 1–12 (2020).

39. Beumer, J. et al. Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat. Cell

Biol. 20, 909–916 (2018).

40. Beumer, J. et al. BMP gradient along the intestinal villus axis controls zonated enterocyte and goblet cell states. Cell Rep. 38, 110438

(2022).

41. Gehart, H. et al. Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. Cell 176, 1158–1173

(2019).

42. Mortensen, K., Christensen, L. L., Holst, J. J. & Orskov, C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small

intestine. Regul. Pept. 114, 189–196 (2003).

43. Svendsen, B. et al. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine.

Endocrinology 156, 847–857 (2015).

Acknowledgements

The authors thank Kyoto University Live Imaging Center and Institute for Integrated Cell-Material Sciences

(iCeMS) and Kyoto University Live Imaging Center for experimental support; Kaori Ikeda (Department of

Diabetes, Endocrinology and Nutrition, Kyoto University) for statistical discussion.

Author contributions

T.H. and N.H. planned the study, researched data, contributed to discussion, wrote, reviewed and edited the

manuscript. S.T., S.Y., E.I.-O., T.K. and T.Y. researched data. H.T. and S.S.-K. supported to analyze images. D.Y.

contributed to discussion. Y.H. provided materials and contributed to discussion. N.I. planned the study, contributed to discussion, edited the manuscript. All authors approved the final version of the manuscript. N.H.

and N.I. are corresponding authors.

Funding

This study was supported by Grants from the Ministry of Education, Culture, Sports, Science and Technology

(MEXT), Japan Society for the Promotion of Science (JSPS) [Grant Nos. 19K09022, 20H03731, and 22K08668],

Ministry of Health, Labour, and Welfare, Ministry of Agriculture, Forestry and Fisheries, Japan Diabetes Foundation, Japan Association for Diabetes Education and Care, Merck Sharp & Dohme (MSD) Life Science Foundation,

Public Interest Incorporated Foundation, and Suzuken Memorial Foundation.

Competing interests N. I. received joint research grants from Daiichi Sankyo Co., Ltd., Terumo Co., Ltd., and Drawbridge, Inc.; N.I.

received speaker honoraria from Kowa Pharmaceutical Co., Ltd.; MSD, Astellas Pharma Inc., Novo Nordisk

Pharma Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical

Co., Ltd., and Mitsubishi Tanabe Pharma Co., Ltd.; N.I. received scholarship grants from Kissei Pharmaceutical

Co., Ltd., Sanofi, Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd.,

Japan Tobacco Inc., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., MSD,

Eli Lilly Japan, Ono Pharmaceutical Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Nippon Boehringer Ingelheim

Co., Ltd., Novo Nordisk Pharma Ltd., Novartis Pharma K.K., Teijin Pharma Ltd., and Life Scan Japan Inc.. N.

H. received scholarship grants from Mitsubishi Tanabe Pharma Co., Ltd., Ono Pharmaceutical Co. Ltd., Sanofi,

and Novo Nordisk Pharma Ltd. All other authors have nothing to disclose.

Additional information

Supplementary Information The online version contains supplementary material available at https://​doi.​org/​

10.​1038/​s41598-​022-​22511-7.

Correspondence and requests for materials should be addressed to N.H. or N.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Scientific Reports |

(2022) 12:17530 |

https://doi.org/10.1038/s41598-022-22511-7

11

Vol.:(0123456789)

www.nature.com/scientificreports/

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

© The Author(s) 2022

Scientific Reports |

Vol:.(1234567890)

(2022) 12:17530 |

https://doi.org/10.1038/s41598-022-22511-7

12

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る